Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Date:10/20/2008

- Planned Cohort of 21 Patients with Non-Small Cell Lung Cancer Enrolled in First Stage of Trial Assessing Regimen of Bavituximab with Carboplatin and

Paclitaxel -

TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, today announced that it has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall tumor response rate in patients receiving the combination therapy.

Peregrine president and CEO Steven W. King noted, "The rapid completion of enrollment in the first stage of this study adds to the positive momentum we have built in our bavituximab clinical program. We look forward to reporting initial data from this trial as patient treatment and follow-up continue and to learning more about bavituximab's potential as a novel targeted therapy for this devastating disease."

In the trial's Simon two-stage design, 21 patients with NSCLC have been enrolled in Stage A of the study. The trial may be expanded to include up to a total of 49 patients if promising results are observed in the initial cohort. Secondary objectives of the study include assessing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients are receiving bavituximab and up to six cycles of carboplatin and paclitaxel, and they may continue to receive bavituximab as long as the cancer does not progress and side effects are acce
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... N.Y. , Dec. 18, 2014 Egenix, Inc. ... has been elected Chairman of the Board, to succeed ... and CEO, but will continue as a member of the ... he has added to the company over almost twenty years, ... The Board of Directors has established a Search Committee ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 “Never ... at Philipps- Universität Marburg’s Department of Physics, advises ... in the newly released SPIE Women in ... be too shy to ask questions.” , In ... engineering, and mathematics) occupations ranging from university professor ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... LA JOLLA, Calif., Nov. 25 TorreyPines Therapeutics, Inc.,(Nasdaq: ... purchased from Eli Lilly & Company,a reduction in certain ... on,net sales of TorreyPines, clinical-stage compounds NGX426 and tezampanel,should ... tier,royalty rate will be reduced three percentage points and ...
... 25 t2cure, a,biopharmaceutical company developing regenerative medicine ... that it has acquired a family of,patents and ... Frankfurt University. , ... for the rapid characterization,of the potency of bone ...
... FRANCISCO, Calif., Nov. 25 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... of new oncology therapeutics for the treatment of solid and hematologic ... following upcoming conferences during the month of December: , ... Annual Health Care Conference , The New ...
Cached Biology Technology:TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application 2Sunesis to Present at Upcoming Conferences 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... If world leaders do not immediately engage in a race ... ecosystems will not survive the global warming and acidification predicted ... group of marine scientists from around the world in a ... 13., "It,s vital that the public understands that the lack ...
... at Stevens Institute of Technology, won first place at ... in November 2007. Freed was the first competitor from ... poster, Impedance Mammography, was based on a project she ... April 2007, the New Jersey Regional ISPE Poster Contest ...
... 20, 2007) -- At its core, healthy neurological function hinges ... the synapse. Figuring out how the synapse traffics this ... understanding the function of the healthy and diseased brain. ... Medical College in New York City has spotted a crucial ...
Cached Biology News:Major study concludes that global warming is killing off coral 2Katherine Freed wins first place at the International ISPE Undergraduate Poster Contest 2A key enzyme helps keep the synapse on track 2A key enzyme helps keep the synapse on track 3
... Cassettes facilitate the hybridization of DNA or ... 25mm x 75mm glass slides. The proprietary ... correct for poor flatness, as is often ... low volume chamber (67uL analytical cavity volume) ...
... This reagent is formulated specifically for Alkaline ... high levels of activity for both the ... at final dilution. This product has ... providing the customer a longer shelf life, ...
... Lambda Free Light Chain ... of human immunoglobulin. Specificity: ... epitope of lambda chain. Reacts with ... lambda chains but not with lambda ...
... The SDSaway reagent is a valuable tool ... The presence of SDS in biological ... tightly bound SDS-protein complex, inhibits enzymatic activity ... presents as a contaminant in mass spectrometry ...
Biology Products: